Current and future biomarkers for pancreatic adenocarcinoma
Although pancreatic cancer is only the twelfth most common type of cancer in the world, it features a very unfavorable prognosis. The mortality rate almost equals the incidence rate, corroborating the very poor prognosis of pancreatic cancer. The 5-year survival rate for all stages of pancreatic duc...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2017-05-01
|
| Series: | Tumor Biology |
| Online Access: | https://doi.org/10.1177/1010428317692231 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849407464227733504 |
|---|---|
| author | Sven H Loosen Ulf P Neumann Christian Trautwein Christoph Roderburg Tom Luedde |
| author_facet | Sven H Loosen Ulf P Neumann Christian Trautwein Christoph Roderburg Tom Luedde |
| author_sort | Sven H Loosen |
| collection | DOAJ |
| description | Although pancreatic cancer is only the twelfth most common type of cancer in the world, it features a very unfavorable prognosis. The mortality rate almost equals the incidence rate, corroborating the very poor prognosis of pancreatic cancer. The 5-year survival rate for all stages of pancreatic ductal adenocarcinoma is only 7%. Surgical resection represents the only potentially curative treatment option for pancreatic ductal adenocarcinoma patients but is often not feasible due to the advanced stage of the disease upon diagnosis. For advanced disease, palliative chemotherapy is the treatment of choice although the regimens available to date are untargeted and have extensive side-effect profiles, making them unsuitable for patients with a low performance status. For this reason, early detection of pancreatic cancer is essential in order to provide patients with an optimal therapeutic approach. Up to the present day, carbohydrate antigen 19-9 is the only diagnostic marker approved by the U.S. Food and Drug Administration but its diagnostic potential is limited due to its restricted sensitivity and specificity, supporting the urgent need for novel biomarkers. In addition, prognostic and treatment-predictive biomarkers might provide essential information regarding personalized treatment decisions for individual patients. In this article, we aim to review current and future diagnostic, prognostic, and treatment-predictive biomarkers for pancreatic cancer. |
| format | Article |
| id | doaj-art-baeb139591294f89976c2e1c1bf8bcff |
| institution | Kabale University |
| issn | 1423-0380 |
| language | English |
| publishDate | 2017-05-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Tumor Biology |
| spelling | doaj-art-baeb139591294f89976c2e1c1bf8bcff2025-08-20T03:36:03ZengSAGE PublishingTumor Biology1423-03802017-05-013910.1177/1010428317692231Current and future biomarkers for pancreatic adenocarcinomaSven H Loosen0Ulf P Neumann1Christian Trautwein2Christoph Roderburg3Tom Luedde4Department of Gastroenterology, Digestive Diseases and Intensive Care Medicine (Department of Medicine III), Division of GI Oncology, University Hospital RWTH Aachen, Aachen, GermanyDepartment of Surgery, University Hospital RWTH Aachen, Aachen, GermanyDepartment of Gastroenterology, Digestive Diseases and Intensive Care Medicine (Department of Medicine III), Division of GI Oncology, University Hospital RWTH Aachen, Aachen, GermanyDepartment of Gastroenterology, Digestive Diseases and Intensive Care Medicine (Department of Medicine III), Division of GI Oncology, University Hospital RWTH Aachen, Aachen, GermanyDepartment of Gastroenterology, Digestive Diseases and Intensive Care Medicine (Department of Medicine III), Division of GI Oncology, University Hospital RWTH Aachen, Aachen, GermanyAlthough pancreatic cancer is only the twelfth most common type of cancer in the world, it features a very unfavorable prognosis. The mortality rate almost equals the incidence rate, corroborating the very poor prognosis of pancreatic cancer. The 5-year survival rate for all stages of pancreatic ductal adenocarcinoma is only 7%. Surgical resection represents the only potentially curative treatment option for pancreatic ductal adenocarcinoma patients but is often not feasible due to the advanced stage of the disease upon diagnosis. For advanced disease, palliative chemotherapy is the treatment of choice although the regimens available to date are untargeted and have extensive side-effect profiles, making them unsuitable for patients with a low performance status. For this reason, early detection of pancreatic cancer is essential in order to provide patients with an optimal therapeutic approach. Up to the present day, carbohydrate antigen 19-9 is the only diagnostic marker approved by the U.S. Food and Drug Administration but its diagnostic potential is limited due to its restricted sensitivity and specificity, supporting the urgent need for novel biomarkers. In addition, prognostic and treatment-predictive biomarkers might provide essential information regarding personalized treatment decisions for individual patients. In this article, we aim to review current and future diagnostic, prognostic, and treatment-predictive biomarkers for pancreatic cancer.https://doi.org/10.1177/1010428317692231 |
| spellingShingle | Sven H Loosen Ulf P Neumann Christian Trautwein Christoph Roderburg Tom Luedde Current and future biomarkers for pancreatic adenocarcinoma Tumor Biology |
| title | Current and future biomarkers for pancreatic adenocarcinoma |
| title_full | Current and future biomarkers for pancreatic adenocarcinoma |
| title_fullStr | Current and future biomarkers for pancreatic adenocarcinoma |
| title_full_unstemmed | Current and future biomarkers for pancreatic adenocarcinoma |
| title_short | Current and future biomarkers for pancreatic adenocarcinoma |
| title_sort | current and future biomarkers for pancreatic adenocarcinoma |
| url | https://doi.org/10.1177/1010428317692231 |
| work_keys_str_mv | AT svenhloosen currentandfuturebiomarkersforpancreaticadenocarcinoma AT ulfpneumann currentandfuturebiomarkersforpancreaticadenocarcinoma AT christiantrautwein currentandfuturebiomarkersforpancreaticadenocarcinoma AT christophroderburg currentandfuturebiomarkersforpancreaticadenocarcinoma AT tomluedde currentandfuturebiomarkersforpancreaticadenocarcinoma |